TriangleAlisertib (NCT06095505)
Alisertib trial for Small Cell Lung Cancer (NCT06095505). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with extensive-stage small-cell lung cancer progressing after one platinum-based regimen and PD-1 or PD-L1 treatment. No more than two prior regimens are allowed.
The idea: alisertib blocks Aurora A kinase, involved in cell division. Patients take it by mouth twice daily on days one through seven of each 21-day cycle. Researchers measure tumor response, response duration, disease control, survival, and safety, including results within biomarker subgroups. Prior Aurora kinase inhibitors are excluded.
This phase 2 study plans 120 patients. Puma Biotechnology sponsors it; 26 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.